MedTrace Logo

Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA

NCT03314051 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 366

Last updated 2017-10-20

No results posted yet for this study

Summary

No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.

Conditions

  • Nasopharyngeal Carcinoma
  • EBV Related Carcinoma

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Principal Investigators

  • Jin-Ching Lin, MD.PhD. · Department of Radiation Oncology, Taichung Veterans General Hospital

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-02
Primary Completion
2013-05-01
Completion
2016-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03314051 on ClinicalTrials.gov